United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), streptococcus viridans group (unii: nnv2379hkr) (streptococcus viridans group - unii:nnv2379hkr), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j33mjj1) - for temporary relief of chronic sore throats, cellulitis, strep infections and tonsillitis. for temporary relief of chronic sore throats, cellulitis, strep infections and tonsillitis.

European Union - English - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologicals for equidae - horses - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - potassium clavulanate, quantity: 7.4 mg/ml (equivalent: clavulanic acid, qty 6.25 mg/ml); amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; hypromellose; aspartame; succinic acid; xanthan gum; colloidal anhydrous silica; flavour - augmentin is indicated in the treatment of the following infections when caused by augmentin sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing s. aureus, e. coli and klebsiella spp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis & klebsiella spp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h.influenzae and m.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and s. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h.influenzae and m.catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin should not require the addition of another antibiotic due to the amoxicillin content of augmentin.

Australia - English - Department of Health (Therapeutic Goods Administration)

nutrition care pharmaceuticals pty ltd - lactobacillus casei, quantity: 7.5 billion organisms; lactobacillus acidophilus, quantity: 7.5 billion organisms; lactobacillus salivarius ssp salivarius, quantity: 3 billion organisms; bifidobacterium longum, quantity: 4.5 billion organisms; lactobacillus plantarum, quantity: 7.5 billion organisms; lactobacillus rhamnosus, quantity: 9 billion organisms; bifidobacterium lactis, quantity: 4.5 billion organisms; streptococcus thermophilus, quantity: 1.5 billion organisms - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; ascorbic acid; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - maintain/support general health and wellbeing ; maintain/support intestinal health ; maintain/support intestinal good/beneficial/friendly flora ; maintain/support small intestine good/beneficial/friendly flora ; maintain/support gastrointestinal system health ; maintain/support gastrointestinal mucosal membrane health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support healthy gastrointestinal immune function

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - misc. intra mammary - amoxycillin as amoxycillin trihydrate antibiotic active 200.0 mg/sg; clavulanic acid as potassium clavulanate antibiotic active 50.0 mg/sg - antibiotic & related - cattle lactating | bovine - mastitis | subclinical mastitis

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ertapenem sodium 209.2 mg/ml equivalent to 200 mg/ml ertapenem free acid - powder for injection - 200 mg/ml - active: ertapenem sodium 209.2 mg/ml equivalent to 200 mg/ml ertapenem free acid excipient: sodium bicarbonate sodium hydroxide water for injection - treatment invanz is indicated for the treatment of patients with moderate to severe infections caused by susceptible strains of micro-organisms, as well as initial empiric therapy prior to the identification of causative organisms in the infections listed below: · complicated intra-abdominal infections · complicated skin and skin structure infections including diabetic lower extremity and diabetic foot infections · community acquired pneumonia · complicated urinary tract infections including pyelonephritis · acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynaecologic infections · bacterial septicaemia prevention invanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage);  ; ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - powder for injection - active: potassium clavulanate 128mg equivalent to clavulanic acid 100 mg (based on 82% potency +5% overage)   ticarcillin sodium 3.838 g equivalent to ticarcillin 3 g (based on 82% potency +5% overage) - the treatment of infections caused by susceptible strains of organisms in the conditions listed below: - septicaemia (including bacteraemia) - lower respiratory tract infections - bone and joint infections - skin and skin structure infections - urinary tract infections - gynaecological infections - surgical prophylaxis appropriate culture and susceptibility tests should be performed in order to isolate and identify organisms causing infection and to determine their susceptibility to timentin. susceptibility to timentin will vary with geography and time and local succeptibility data should be consulted where available. in certain infections, when the causative organisms are unknown, timentin may be administered in conjunction with an aminoglycoside as initial therapy. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal hysterectomy, abdominal surgery, and colorectal surgery when there is a significant risk of postoperative infection or where occurrence of postoperative infection is considered to be especially serious.